看一下那个临床试验的key inclusions/exclusion’s criteria 吧:https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination.
看一下那个临床试验的key inclusions/exclusion’s criteria 吧:https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination. Rutang48 发表于 2022-12-28 17:27
降压药 与辉瑞新药可一同安全应用的降压药: 氢氯噻嗪 Hydroflumethiazide 点评:虽然安全,但这个药作为降压药而单独应用的情况比较少。 应用辉瑞新药时,需要调整剂量或暂停用药的降压药: 氨氯地平 Amlodipine 点评:辉瑞新药,使氨氯地平浓度加倍也就是相当于剂量加倍。 尼福地平 Nifedipine 非洛地平 Felodipine 地尔硫卓 Diltiazem 维拉帕米 Verapamil 多沙唑嗪 Doxazosin 点评:对五大类降压药的集中表述不好,在下面的“心衰药物”部分,还要涉及其它降压药。 心衰治疗药和部分降压药 与辉瑞新药可一同安全应用的降压药: 转换酶抑制剂(各种带“普利”两个字或者结尾带了“Pril”的药物) 坎地沙坦 Candesartan 奥美沙坦 Olmesartan 替米沙坦 Telmisartan 螺内酯 Spironolactone 恩格列净 Empagliflozin 达格列净 Dapagliflozin 卡格列净 Canagliflozin 夫拉塞米 Furosemide 托拉塞米 Torsemide 美托拉宗 Metolazone 氯噻酮 Chlorthalidone 点评:安全的药物比较多,其中不少也是降压药 应用辉瑞新药时,需要调整剂量或暂停用药的降压药: 厄贝沙坦 Irbesartan 点评:辉瑞新药使厄贝沙坦的浓度降低,降压效果下降。 氯沙坦 Losartan 缬沙坦 Valsartan 沙库巴曲/缬沙坦 Sacubitril/valsartan 点评:辉瑞新药使上述三个心衰/降压药的浓度增加,需要在医生的指导下调整剂量或换用其它更全的药物。 地高辛 Digoxin 点评:辉瑞新药使地高辛的浓度增加,地高辛的安全窗口很小,需要在医生的指导下调整剂量。 用辉瑞新药时,不能用的药: 依普利酮 Eplerenone 点评:因为克服螺内酯致男性乳腺发育的副作用,依普利酮是螺内酯的替代药,但辉瑞新药禁忌和依普利酮合用,在用辉瑞新药期间,可回到螺内酯几天。
感谢楼主!很及时,很有用!
Mark
果然 估计做临床试验的时候把有基础病的都排除了
不懂什么叫双盲实验就别自作聪明了。没人把刀架在老人脖子上逼着他们吃辉瑞
谢谢。
楼主好人一生平安!
想起当初gilead那个,被大妈们夸成啥了,最后治了个寂寞
层主说的是对的,双盲前已经把不符合条件的人群排除了。
看一下那个临床试验的key inclusions/exclusion’s criteria 吧:https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf
Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination.
我妈得的时候幸亏没吃 😓 她有高血压 家庭医生也没说 😓
这。。。这不是说有基础病的才能入组吗?
啊,知道了,你是反驳上一个层主。
这玩意儿,爱信不信呗。
是啊,这里不是说参与者要有以下至少一种基础病吗?我理解错了吗?
Thanks for sharing
这个我也不太清楚,可能得问一下给你家人开这个药的医生?